Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
AbstractBackgroundTo evaluate the efficacy of short-term lurasidone in antipsychotic treatment-naïve (TN) adolescents with schizophrenia versus those treated previously (TP) with antipsychotics.MethodsPatients aged 13–17 with schizophrenia, and a Positive and Negative Symptom Scale (PANSS) score ≥ 7...
Main Authors: | Christoph U. Correll, Michael Tocco, Jay Hsu, Robert Goldman, Andrei Pikalov |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-01-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822000116/type/journal_article |
Similar Items
-
Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
by: Isabella Costamagna, et al.
Published: (2021-01-01) -
Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
by: A. Jones, et al.
Published: (2022-06-01) -
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023-09-01) -
The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
by: Andrea Fiorillo, et al.
Published: (2024-02-01) -
Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
by: F. Calisti, et al.
Published: (2021-04-01)